Expertise in
3
conditions

Dr. Mohamed A. El-Shahawy

Endocrinology
1510 S Central Ave, 
Glendale, CA 
Accepting New Patients
Referral required
Before you request
Expertise in
3
conditions
1510 S Central Ave, 
Glendale, CA 

Overview

Mohamed El-Shahawy is an Endocrinologist practicing medicine in Glendale, California.

Dr. El-Shahawy is highly rated in 3 conditions, according to our data. His clinical expertise encompasses End-Stage Renal Disease (ESRD), Gallbladder Disease, Type 1 Diabetes (T1D), Islet Cell Transplantation, and Gastrostomy.

Dr. El-Shahawy is board certified in American Board Internal Medicine. He is actively involved in clinical research, co-authoring 11 peer reviewed articles and participating in 10 clinical trials. Dr. El-Shahawy is currently accepting new patients.

Specialties

Endocrinology

Licenses

Internal Medicine in CA

Board Certifications

American Board Internal Medicine

Fellowships

LAC-USC Medical Center , Nephrology , 1988 - 1989

Hospital Affiliations

Keck Hospital Of USC
Monterey Park Hospital
Coast Plaza Hospital
Garfield Medical Center
Saint Francis Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Academic Medical Research Institute
1510 S Central Ave, Glendale, CA 91204

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function
Enrollment Status: Active_not_recruiting
Publish Date: June 04, 2026
Intervention Type: Drug
Study Drug: Atrasentan
Study Phase: Phase 3
A Phase 2, Open-Label, Basket Study of Atrasentan in Patients With Proteinuric Glomerular Diseases
A Phase 2, Open-Label, Basket Study of Atrasentan in Patients With Proteinuric Glomerular Diseases
Enrollment Status: Active_not_recruiting
Publish Date: June 01, 2026
Intervention Type: Drug
Study Drug: Atrasentan
Study Phase: Phase 2
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of Lademirsen (SAR339375) for Subcutaneous Injection Administered Every Week in Patients With Alport Syndrome
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of Lademirsen (SAR339375) for Subcutaneous Injection Administered Every Week in Patients With Alport Syndrome
Enrollment Status: Terminated
Publish Date: September 11, 2025
Intervention Type: Drug
Study Drug: Iademirsen
Study Phase: Phase 2
A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome
A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome
Enrollment Status: Completed
Publish Date: June 11, 2025
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
An Extended Access Program to Assess Long Term Safety of Bardoxolone Methyl in Patients With Chronic Kidney Disease
An Extended Access Program to Assess Long Term Safety of Bardoxolone Methyl in Patients With Chronic Kidney Disease
Enrollment Status: Terminated
Publish Date: June 03, 2025
Intervention Type: Drug
Study Drug: Bardoxolone
Study Phase: Phase 3
A Phase 3 Randomized, Open-label (Sponsor-blind), Active-controlled, Parallel-group, Multi-center, Event Driven Study in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease to Evaluate the Safety and Efficacy of Daprodustat Compared to Darbepoetin Alfa
A Phase 3 Randomized, Open-label (Sponsor-blind), Active-controlled, Parallel-group, Multi-center, Event Driven Study in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease to Evaluate the Safety and Efficacy of Daprodustat Compared to Darbepoetin Alfa
Enrollment Status: Completed
Publish Date: April 02, 2024
Intervention Type: Drug
Study Drugs: Daprodustat, Darbepoetin Alpha
Study Phase: Phase 3
Randomized, Multicenter, Double-blind, Parallel-Group, Placebo & Comparator-Controlled Study to Compare the Glycemic Effects, Safety & Tolerability of Metformin Delayed-Release Tablets in Patients With Type 2 Diabetes Mellitus
Randomized, Multicenter, Double-blind, Parallel-Group, Placebo & Comparator-Controlled Study to Compare the Glycemic Effects, Safety & Tolerability of Metformin Delayed-Release Tablets in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Suspended
Publish Date: March 14, 2023
Intervention Type: Drug
Study Drug: Metformin
Study Phase: Phase 3
A Phase 1, Open-Label Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of RG-012 for Injection, Including Its Effect on Renal microRNA-21, in Subjects With Alport Syndrome
A Phase 1, Open-Label Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of RG-012 for Injection, Including Its Effect on Renal microRNA-21, in Subjects With Alport Syndrome
Enrollment Status: Completed
Publish Date: April 25, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1b, Multicenter, Open-Label, Adaptive Design Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RGLS4326 Administered Via SC Injection to Patients With Autosomal Dominant Polycystic Kidney Disease
A Phase 1b, Multicenter, Open-Label, Adaptive Design Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RGLS4326 Administered Via SC Injection to Patients With Autosomal Dominant Polycystic Kidney Disease
Enrollment Status: Completed
Publish Date: December 15, 2021
Intervention Type: Drug
Study Drug: RGLS4326
Study Phase: Phase 1
A 52-week Open-label (Sponsor-blind), Randomized, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Efficacy and Safety of Daprodustat Compared to Recombinant Human Erythropoietin in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Initiating Dialysis
A 52-week Open-label (Sponsor-blind), Randomized, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Efficacy and Safety of Daprodustat Compared to Recombinant Human Erythropoietin in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Initiating Dialysis
Enrollment Status: Completed
Publish Date: October 20, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

11 Total Publications

Shorter Digestion Times of Donor Islets Is Associated With Better Islet Graft Function After Islet Transplantation.
Shorter Digestion Times of Donor Islets Is Associated With Better Islet Graft Function After Islet Transplantation.
Journal: Cell transplantation
Published: January 30, 2025
Similar Doctors
Expertise in
42
conditions
Expertise in
42
conditions
Referral required
Before you request

Keck Hospital Of USC

1500 San Pablo Street, 
Los Angeles, CA 
 (5.5 miles away)
800-872-2273
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Carmichael is an Endocrinologist practicing medicine in Los Angeles, California. Dr. Carmichael is highly rated in 42 conditions, according to our data. His clinical expertise encompasses Pituitary Tumor, Hypothalamic Tumor, Acromegaly, Endoscopic Transnasal Transsphenoidal Surgery, and Endoscopy. Dr. Carmichael is currently accepting new patients.

Expertise in
15
conditions
Dr. Trevor E. Angell
Endocrinology
Expertise in
15
conditions
Dr. Trevor E. Angell
Endocrinology
Referral required
Before you request

Norris Cancer Hospital-Pasadena

625 S Fair Oaks Ave, 
Pasadena, CA 
 (6.1 miles away)
626-568-1622
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Trevor Angell is an Endocrinologist practicing medicine in Pasadena, California. He has been practicing medicine for over 17 years. Dr. Angell is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Thyroid Nodule, Thyroid Cancer, Follicular Thyroid Cancer, Papillary Thyroid Cancer, and Thyroidectomy. Dr. Angell is currently accepting new patients.

Expertise in
37
conditions
Dr. Anthony P. Heaney
Endocrinology
Expertise in
37
conditions
Dr. Anthony P. Heaney
Endocrinology
Referral required
Before you request

Gonda (Goldschmied) Diabetes Center Santa Monica

2020 Santa Monica Blvd Ste 550, 
Santa Monica, CA 
 (14.2 miles away)
310-828-1050
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Anthony Heaney is an Endocrinologist practicing medicine in Santa Monica, California. Dr. Heaney is highly rated in 37 conditions, according to our data. His clinical expertise encompasses Cushing's disease, Pituitary Tumor, Hypothalamic Tumor, Cushing's syndrome, and Endoscopic Transnasal Transsphenoidal Surgery. Dr. Heaney is currently accepting new patients.

Frequently Asked Questions about Dr. Mohamed A. El-Shahawy

How do I make an appointment with Dr. Mohamed A. El-Shahawy?

You can book an appointment with Dr. Mohamed A. El-Shahawy by calling their office at 818-956-2111. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mohamed A. El-Shahawy a top-rated expert for End-Stage Renal Disease (ESRD)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mohamed A. El-Shahawy is classified as an Distinguished expert for End-Stage Renal Disease (ESRD), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mohamed A. El-Shahawy specialize in?

While Dr. Mohamed A. El-Shahawy is a Endocrinology, they have specific expertise in End-Stage Renal Disease (ESRD), Gallbladder Disease, and Islet Cell Transplantation. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Endocrinology.

Does Dr. Mohamed A. El-Shahawy participate in research or clinical trials?

Yes. Dr. Mohamed A. El-Shahawy has published 11 articles and abstracts on conditions like End-Stage Renal Disease (ESRD). You can view a list of Dr. Mohamed A. El-Shahawy's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mohamed A. El-Shahawy accept my insurance?

Dr. Mohamed A. El-Shahawy accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 818-956-2111 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. El-Shahawy's expertise for a condition
ConditionClose
    View All 13 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile